Possibilities of therapy for neuromyelitis optica spectrum disorders
https://doi.org/10.17650/2073-8803-2021-16-4-49-58
Abstract
Neuromyelitis optica spectrum disorders are rare chronic autoimmune inflammatory demyelinating diseases of the central nervous system. Considering that the increase in neurological deficit in neuromyelitis optica spectrum disorders is mainly due to repeated exacerbations, the goals of pharmacotherapy are represented by the relief of relapses and the prevention of their development. Information about indications for therapy and side effects is necessary to identify the benefits and risks for patients with neuromyelitis optica spectrum disorders in each individual case.
Keywords
neuromyelitis optica spectrum disorders,
antibodies to myelinoligodendrocyte glycoprotein,
antibodies to aquaporin 4,
interleukin 6,
anti-B-cell therapy
Supporting agencies: This article was prepared with the support of Roche.
About the Author
E. S. Novikova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Еkaterina Sergeevna Novikova
129110, Moscow, Shchepkina St., 61/2
References
1. Boyko A.N., Smirnova N.F., Shchukin I.A. et al. Ofatumumab is a new drug for the treatment of multiple sclerosis. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = Journal of Neurology and Psychiatry S.S. Korsakov 2021;121(7 issue 2):1–8. (In Russ.).
2. Kotov A.S., Novikova E.S., Metkechekova Yu.V. Clinical polymorphism of anti-MOG-associated demyelinating diseases. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = Journal of Neurology and Psychiatry S.S. Korsakov 2020;120(12):95–101. (In Russ.).
3. Kotov S.V., Novikova E.S., Kotov A.S. Anti-B-cell therapy in patients with neuromyelitis optica spectrum disorders. Nevrologiya, neyropsihiatriya, psihosomatika = Neurology, neuropsychiatry, psychosomatics 2021;13(4):18–24. (In Russ.).
4. Simaniv T.O., Vasiliev A.V., Askarova L.Sh., Zakharova M.N. Opticomyelitis and diseases of the opticoneuromyelitis spectrum. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = Journal of Neurology and Psychiatry S.S. Korsakov 2019;119(10 issue 2):35–48. (In Russ.).
5. Araki M., Aranami T., Matsuoka T. et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013;23:827–31. DOI:10.1007/s10165-012-0715-9.
6. Asseyer S., Cooper G., Paul F. Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms and current treatment strategies. Front Neurol 2020;11:778. DOI:10.3389/fneur.2020.00778.
7. Asseyer S., Schmidt F., Chien C. et al. Pain in AQP4-IgG-positive and MOGIgG-positive neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin 2018;4(3):2055217318796684. DOI:10.1177/2055217318796684.
8. Ataie-Kachoie P., Pourgholami M.H., Morris D.L. Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine Growth Factor Rev 2013;24:163–73. DOI:10.1371/journal.pone.0060817.
9. Ayzenberg I., Kleiter I., Schröder A., Hellwig K. el al. Interleukin 6 receptor blockade in patients with neuromyelitis optica non responsive to anti-CD20 therapy. JAMA Neurol 2013;70:394–7. DOI:10.1001/jamaneurol.2013.1246.
10. Baker D., Pryce G., James L.K. et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020;44:102279. DOI:10.1016/j.msard.2020.102279.
11. Beekman J., Keisler A., Pedraza O. et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. Neurol Neuroimmunol Neuroinflamm 2019;6(4):e580. DOI:10.1212/NXI.0000000000000580.
12. Bennett J.L., O’Connor K.C., Bar-Or A. et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2(3):1–11. DOI:10.1212/NXI.0000000000000104.
13. Braun N., Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher 1999;3:240–5. DOI:10.1046/j.1526-0968.1999.00155.x.
14. Chavarro V.S., Mealy M.A., Simpson A. et al. Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;e286. DOI:10.1212/NXI.0000000000000286.
15. Ciron J., Audoin B., Bourre B. et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol 2018;174(4):255–64. DOI:10.1016/j.neurol.2017.11.005.
16. Collongues N., Brassat D., Maillart E. et al. Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler J 2016;22:955–9. DOI:10.1177/1352458515602337.
17. Cree B.A., Bennett J.L., Kim H.J. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352–63. DOI:10.1016/S0140-6736(19)31817-3.
18. Damato V., Evoli A., Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016;73:1342–8. DOI:10.1001/jamaneurol.2016.1637.
19. De Souza Moraes A., Brum D.G., Ierich J.C. et al. A highly specific and sensitive nanoimmunosensor for the diagnosis of neuromyelitis optica spectrum disorders. Scientific Rep 2019;9(1):1–9. DOI:10.1038/s41598-019-52506-w.
20. Dienz O., Eaton S.M., Bond J.P. et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009;206:69–78. DOI:10.1038/s41598-019-52506-w.
21. Espiritu A.I. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Mult Scler Rel Disord 2019;33:22–32. DOI:10.1016/j.msard.2019.05.011.
22. Forsthuber T.G., Cimbora D.M., Ratchford J.N. et al. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord 2018;11:175628641876169. DOI:10.1177/1756286418761697.
23. Frampton J.E. Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs 2020;80(7):719–27. DOI:10.1007/s40265-020-01297-w.
24. Fryer J.P., Lennon V.A., Pittock S.J. et al. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm 2014;1(1). DOI:10.1212/NXI.0000000000000011.
25. Gao Y., Zhang B., Yang J. Satralizumab for the treatment of neuromyelitis optica spectrum disorders. Ann Pharmacother 2021;55(9):1167–71. DOI:10.1177/1060028020976669.
26. Hinson S.R., McKeon A., Fryer J.P. et al. Prediction of neuromyelitis optica attack severity by quantitation of complementmediated injury to aquaporin4expressing cells. Arch Neurol 2009;66:1164–67. DOI:10.1001/archneurol.2009.188.
27. Icoz S., Tuzun E., Kurtuncu M. et al. Enhanced IL-6 production in aquaporin-4 anti-body positive neuromyelitis optica patients. Int J Neurosci 2010;120:71–5. DOI:10.3109/00207450903428970.
28. Jacob A., Weinshenker B.G., Violich I. et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008;65:1443–8. DOI:10.1001/archneur.65.11.noc80069.
29. Kim S.H., Kim W., Li X.F. et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011;68:1412–20. DOI:10.1001/archneurol.2011.154.
30. Kimbrough D., Fujihara K., Jacob A. et al. Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 2012;1:180–7. DOI:10.1016/j.msard.2012.06.002.
31. Kitley J., Waters P., Woodhall M. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol 2014;71(3):276. DOI:10.1001/jamaneurol.2013.5857.
32. Lee C., Ka-Fung H., Chiu P. et al. Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. J Magn Reson Imaging 2017;47(6):1601–9. DOI:10.1002/jmri.25866.
33. Lennon V.A., Wingerchuk D.M., Kryzer T.J. et al. A serum autoantibody marker of neuromyelitisoptica: distinction from multiple sclerosis. Lancet 2004;364:2106–12. DOI:10.1016/S0140-6736(04)17551-X.
34. Levy M., Fujihara K., Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;1:60–7. DOI:10.1016/S1474-4422(20)30392-6.
35. Lunemann J., Nimmerjahn F., Dalakas M.C. Intravenous immunoglobulin in neurology. Mode of action and clinical efficacy. Nat Rev Neurol 2015;11:80–9. DOI:10.1038/nrneurol.2014.253.
36. Matsushita T., Tateishi T., Isobe N. et al. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica relapsing remitting or primary progressive multiple sclerosis. PLoS One 2013;8:e61835. DOI:10.1371/journal.pone.0061835.
37. Nakamura M., Nakazawa T., Doi H. et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefe’s Arch Clin Exp Ophthalmol 2010;248: 1777–85. DOI:10.1007/s00417-010-1344-7.
38. Palanichamy A., Jahn S., Nickles D. et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 2014;193:580–6. DOI:10.4049/jimmunol.1400118.
39. Pellkofer H.L., Krumbholz M., Berthele A. et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310–5. DOI:10.1212/WNL.0b013e3182152881.
40. Salama S., Khan M., Pardo S. et al. MOG antibody–associated encephalomyelitis/encephalitis. Mult Scler J 2019;25(11):1427–33. DOI:10.1177/1352458519837705.
41. Sato D.K., Nakashima I., Takahashi T. et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013;80(24):2210–6. DOI:10.1212/WNL.0b013e318296ea08.
42. Schuh E., Berer K., Mulazzani M. et al. Features of human CD3+CD20+ T cells. J Immunol 2016;197:1111–7. DOI:10.4049/jimmunol.1400118.
43. Sellner J., Boggild M., Clanet M. et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019–32. DOI:10.1038/s41598-019-52506-w.
44. Stiebel-Kalish H., Hellmann M.A., Mimouni M. et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optica neuritis? Neurol Neuroimmunol Neuroinflamm 2019;6:e572. DOI:10.1212/NXI.0000000000000572.
45. Traboulsee A., Greenberg B.M., Bennett J.L. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomized, double-blind, multicenter, placebo-controlled phase 3 trial. Lancet Neurol 2020;19:402–12. DOI:10.1016/S1474-4422(20)30078-8.
46. Tradtrantip L., Felix C.M., Spirig R. et al. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 2018;133:345–53. DOI:10.1016/j.neuropharm.2018.02.002.
47. Trebst C., Jarius S., Berthele A. et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1–16. DOI:10.1007/s00415-013-7169-7.
48. Uchida T., Mori M., Uzawa A. et al. Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood-brain barrier disruption. Mult Scler 2017;23:1072–84. DOI:10.1177/1352458516672015.
49. Uzawa A., Mori M., Arai K. et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16:1443–52. DOI:10.1177/1352458510379247.
50. Uzawa A., Mori M., Masuda H. et al. Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: a special focus on neuromyelitis optica. Clin Chim Acta 2017;469:144–9. DOI:10.1016/j.cca.2017.03.006.
51. Wallach A.I., Tremblay M., Kister I. Advances in the treatment of neuromyelitis optica spectrum disorder. Neurol Clin 2021;39(1):35–49. DOI:10.1016/j.ncl.2020.09.003.
52. Wang H.H., Dai Y.Q., Qiu W. et al. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 2011;18:1313–7. DOI:10.1016/j.jocn.2011.01.031.
53. Weber M.S., Derfuss T., Metz I., Brück W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Therc Adv Neurol Disord. 2018;11:1756286418762083. DOI:110.1177/1756286418762083.
54. Wingerchuk D.M., Banwell B., Bennett J.L. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177–89. DOI:10.1212/WNL.0000000000001729.
55. Wingerchuk D.M., Lennon V.A., Pittock S.J. et. al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–9. DOI:10.1212/01.wnl.0000216139.44259.74.
56. Yamamura T., Kleiter I., Fujihara K. et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:2114–24. DOI:10.1056/NEJMoa1901747.
57. Yang C.S., Yang L., Li T. et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013;81:710–3. DOI:10.1212/WNL.0b013e3182a1aac7.
58. Yao X., Verkman A.S. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun 2017;5:57. DOI:10.1186/s40478-017-0462-4.
Review
For citations:
Novikova E.S. Possibilities of therapy for neuromyelitis optica spectrum disorders. Russian Journal of Child Neurology. 2021;16(4):49-58. (In Russ.) https://doi.org/10.17650/2073-8803-2021-16-4-49-58
Views:
576
Email this article 